m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02836)
Name
PT-14
Synonyms
Erectide; PT-14 (transmucosal); PT-14 (transmucosal), Palatin/TheraTech
    Click to Show/Hide
Status
Discontinued in Phase 2
Structure
Formula
C14H20N2O2
InChI
1S/C14H20N2O2/c15-13-7-2-1-6-12(13)14(17)18-10-8-11-5-3-4-9-16-11/h1-2,6-7,11,16H,3-5,8-10,15H2
InChIKey
BMIJYAZXNZEMLI-UHFFFAOYSA-N
PubChem CID
6875
TTD Drug ID
D09XVQ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Melanocortin receptor 4 (MC4R)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Melanocortin receptor 4 (MC4R) is a therapeutic target for PT-14. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of PT-14 through regulating the expression of Melanocortin receptor 4 (MC4R). [1], [2]
References
Ref 1 Demethyltransferase FTO alpha-ketoglutarate dependent dioxygenase (FTO) regulates the proliferation, migration, invasion and tumor growth of prostate cancer by modulating the expression of melanocortin 4 receptor (MC4R). Bioengineered. 2022 Mar;13(3):5598-5612. doi: 10.1080/21655979.2021.2001936.
Ref 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.